Clinical Study on the Antiplatelet Aggregation Effect of Ticlopidine Hydrochloride(Ticlid®)

Oh, Byung Heui; Lee, Myoung Mook; Park, Young Bae; Choi, Yun Sik; Seo, Jung Don; Lee, Young Woo

doi:10.4070/kcj.1986.16.3.379

Korean Circ J. 1986 Sep;16(3):379-387. Korean.
Published online Sep 30, 1986.
https://doi.org/10.4070/kcj.1986.16.3.379

Original Article

Clinical Study on the Antiplatelet Aggregation Effect of Ticlopidine Hydrochloride(Ticlid®)

Byung Heui Oh, M.D., Myoung Mook Lee, M.D., Young Bae Park, M.D., Yun Sik Choi, M.D., Jung Don Seo, M.D. and Young Woo Lee, M.D.

Author information

Author notes

Copyright and License

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The antiplatelet aggregation effect of ticlopidine was studied in 22 cases of coronary artery disease(CAD) and 17 cases of control by obseving changes of plarma β-thromboglobulin(β-TG) and platelet factor 4(PF-4) before and after administration of ticlopidine 500mmg daily for 2 weeks.

1) Compared with the controls, CAD patients had significantly greater plasm levels of β-TG(52.6±32.7ng/ml. mean ±SD vs. 91.0±52.0, P<0.05) and PF-4(17.5±12.8 ng/ml vs. 32.9±24.5, P<0.05).

2) In controls, plasma levels of β-TG and PF-4 didn't change significantly after taking ticlopidine.

3) In CAD patients, plasma levels of β-TG (91.0±52.0ng/ml vs. 53.9±20.0, P<0.05) and PF-4(32.9±24.5ng/ml vs. 18.8 ±11.9(P<0.05) decreased significantly after ticlopidine.

4) The side effects were observed in 2 cases such as mild indigestion and urticaria.